Opportunity Information: Apply for RFA AR 11 005
Apply for RFA AR 11 005
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitive Revision Award (P01 and P50)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Feb 26, 2010 and posted on Feb 26, 2010.
- Applicants must submit their applications by Aug 4, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts Public and State controlled institutions of higher education City or township governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (RFA-AR-11-005) is a National Institutes of Health program from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) focused on accelerating the translation of tissue engineering and regenerative medicine (TE/RM) advances for musculoskeletal and skin conditions. The core idea is to push promising TE/RM therapies and enabling platforms out of earlier-stage research and into the kind of preclinical evidence package that can realistically support near-term first-in-human studies. Rather than funding brand-new standalone projects, NIAMS is offering competitive revision support (what used to be called a competing supplement) to expand the scope of already active NIAMS-funded parent awards so investigators can complete major translational steps that are often too large or costly to handle under the original grant budget and timeline.
A defining feature of the announcement is its emphasis on large animal preclinical studies. NIAMS is explicitly looking for work in species and models that more closely approximate human anatomy, biomechanics, and physiology than typical rodent work, because the goal is to generate data that can directly support Phase I/II clinical trials or immediately set up the path to those trials. Applications are expected to do at least one of three things: (1) generate the specific preclinical data needed to justify and design Phase I/II studies in musculoskeletal or skin TE/RM, (2) demonstrate efficacy of a TE/RM therapy in a large animal context where the results are meaningfully predictive for humans, or (3) develop or refine preclinical large animal models that can serve as a practical bridge to Phase I/II clinical testing for TE/RM approaches. In contrast, early translational studies limited to small animals (for example rodents or rabbits) are called out as not responsive to the announcement, which signals that reviewers will be looking for a clear rationale for large animal selection, clinically relevant endpoints, and a direct line of sight to human trial readiness.
The mechanism is specifically a revision to existing P01 and P50 awards. That means only investigators with active NIAMS parent grants of the appropriate type can use this route to request additional, competitively reviewed support to add substantial translational activities to their ongoing program project (P01) or specialized center (P50). NIAMS notes that this P01/P50 revision opportunity runs in parallel with a companion announcement of identical scientific scope aimed at the R01 community (RFA-AR-11-004), which collectively indicates an institute-wide push to move the most mature TE/RM concepts toward clinical entry regardless of whether the underlying parent grant is investigator-initiated (R01) or multi-project/center-based (P01/P50).
Funding is limited and competitive. NIAMS planned to commit a total of $1,000,000 in FY 2011 to make 1 to 3 ART awards across both the R01 and the P01/P50 ART announcements combined, so the number of awards under this specific FOA would be a subset of that total. Awards are also contingent on the availability of funds and the receipt of sufficiently strong applications, reinforcing that only projects with clear translational urgency, strong feasibility, and compelling clinical relevance are likely to be supported.
Eligibility, as listed in the source data, is broad in terms of institution type and includes many domestic public and private entities (such as higher education institutions, nonprofits, small businesses, and various government units), as well as certain non-U.S. entities and other special categories (including HBCUs, Hispanic-serving institutions, tribal organizations, and U.S. territories/possessions). Practically, though, the key gating requirement is that applicants must be positioned to submit a competitive revision tied to an active, eligible NIAMS parent P01 or P50 grant, since the award is not designed as an independent grant for new applicants without an appropriate parent award to revise.
Administratively, the opportunity was posted February 26, 2010, with an application due date of August 4, 2010, and an archive date of September 4, 2010. It falls under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), has no cost sharing or matching requirement, and is categorized as a discretionary health research grant. The full announcement was hosted through the NIH grants guide, and NIH’s Office of Extramural Research provided standard web support contacts for access and linking issues.
Frequently Asked Questions (FAQs) - NIH NIAMS RFA-AR-11-005
What is RFA-AR-11-005?
RFA-AR-11-005 is a National Institutes of Health (NIH) funding opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). It supports activities intended to accelerate translation of tissue engineering and regenerative medicine (TE/RM) advances for musculoskeletal and skin conditions toward clinical testing.
What is the overall goal of this funding opportunity?
The goal is to move promising TE/RM therapies and enabling platforms from earlier-stage research into a preclinical evidence package that can realistically support near-term first-in-human studies, including preparation for Phase I/II clinical trials.
Is this opportunity meant for brand-new standalone projects?
No. This opportunity is for competitive revision support (formerly called a competing supplement) to expand the scope of already active NIAMS-funded parent awards, rather than funding new independent projects.
What NIH grant mechanism does this opportunity use?
This announcement supports revisions to existing P01 (program project) and P50 (specialized center) awards. Only investigators with active, eligible NIAMS parent P01 or P50 grants can use this mechanism.
What types of studies does NIAMS emphasize under this announcement?
A defining emphasis is on large animal preclinical studies, using species and models that more closely approximate human anatomy, biomechanics, and physiology than typical rodent studies. The intent is to generate data that can directly support entry into Phase I/II trials or clearly set up the path to those trials.
What kinds of projects are considered responsive to this announcement?
Applications are expected to do at least one of the following:
- Generate specific preclinical data needed to justify and design Phase I/II studies in musculoskeletal or skin TE/RM.
- Demonstrate efficacy of a TE/RM therapy in a large animal context where results are meaningfully predictive for humans.
- Develop or refine preclinical large animal models that can serve as a practical bridge to Phase I/II clinical testing for TE/RM approaches.
Are small animal studies allowed under this opportunity?
Early translational studies limited to small animals (for example rodents or rabbits) are specifically described as not responsive. The announcement signals that applications should provide a clear rationale for large animal selection, clinically relevant endpoints, and a direct line of sight to human trial readiness.
What disease or condition areas does this opportunity target?
The scientific focus is on musculoskeletal and skin conditions, specifically in the context of tissue engineering and regenerative medicine (TE/RM).
Who is eligible to apply?
The listed institutional eligibility is broad and includes many domestic public and private entities (such as higher education institutions, nonprofits, small businesses, and various government units), as well as certain non-U.S. entities and other special categories (including HBCUs, Hispanic-serving institutions, tribal organizations, and U.S. territories/possessions). However, the key requirement is that the application must be a competitive revision tied to an active, eligible NIAMS parent P01 or P50 award.
Can an organization apply if it does not currently have an active NIAMS P01 or P50 parent award?
Not through this specific mechanism as described. The opportunity is designed as a competitive revision to an existing, active, eligible NIAMS P01 or P50 parent grant, not as an independent award for new applicants without the appropriate parent award.
How does this opportunity relate to RFA-AR-11-004?
NIAMS noted a companion announcement with identical scientific scope aimed at the R01 community (RFA-AR-11-004). Together, these announcements indicate an institute-wide push to move mature TE/RM concepts toward clinical entry, whether the parent grant is an R01 or a multi-project/center-based P01/P50.
How much funding was planned, and how many awards were expected?
NIAMS planned to commit a total of $1,000,000 in FY 2011 to make 1 to 3 ART awards across both the R01 and the P01/P50 ART announcements combined. The number of awards under RFA-AR-11-005 would be a subset of that combined total.
Is funding guaranteed if an application is submitted?
No. Awards are contingent on the availability of funds and the receipt of sufficiently strong applications, and the program is described as limited and competitive.
When was this opportunity posted, and what were the key dates?
The opportunity was posted on February 26, 2010. The application due date was August 4, 2010. The archive date was September 4, 2010.
What CFDA number is associated with this funding opportunity?
The opportunity falls under CFDA 93.846, Arthritis, Musculoskeletal and Skin Diseases Research.
Is there a cost sharing or matching requirement?
No. The source information states there is no cost sharing or matching requirement.
How is this opportunity categorized?
It is categorized as a discretionary health research grant.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide.
Who provided support contacts for access or linking issues?
NIH's Office of Extramural Research provided standard web support contacts for access and linking issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: ARRA Equipment to Enhance Training for Health Professionals Nursing Workforce Diversity
Previous opportunity: NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitve Revision Award (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AR 11 005
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AR 11 005) also looked into and applied for these:
| Funding Opportunity |
|---|
| Indo U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03) Apply for PA 10 115 Funding Number: PA 10 115 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Support Establishment and Sustainability of Medical Waste Management Systems in the Republic of Kenya under the President s Emergency plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10135 Funding Number: CDC RFA PS10 10135 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Production Of Human Proteins To Be Used For Generating Affinity Reagents (U01) Apply for RFA RM 10 007 Funding Number: RFA RM 10 007 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Providing a Comprehensive Continuum of HIV/AIDS Care and Treatment Services in the Democratic Republic of Congo Under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10132 Funding Number: CDC RFA PS10 10132 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| ARRA Equipment to Enhance Training for Health Professionals Preventive Medicine Residency Program Apply for HRSA 10 180 Funding Number: HRSA 10 180 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Large Scale Production of Perturbagen Induced Cellular Signatures (U54) Apply for RFA RM 10 003 Funding Number: RFA RM 10 003 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM Apply for DHAPPBAA10 001 Funding Number: DHAPPBAA10 001 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| APHIAplus PROGRAM DESCRIPTION Apply for RFA 623 10 000009 Funding Number: RFA 623 10 000009 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $76,000,000 |
| MCH Research Network on Pregnancy Related Care Apply for HRSA 10 088 Funding Number: HRSA 10 088 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season (U18) Apply for RFA IP 10 007 Funding Number: RFA IP 10 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Maintaining Collection of National Violent Death Reporting System (NVDRS) Data, NCIPC Apply for CE08 80203CONT10 Funding Number: CE08 80203CONT10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Maintaining Collection of National Violent Death Reporting System (NVDRS) Data, NCIPC Apply for CE07 70404CONT10 Funding Number: CE07 70404CONT10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Development of the National Violent Death Reporting System (NVDRS), NCIPC Apply for CE09 90402CONT10 Funding Number: CE09 90402CONT10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Promoting Extensive Implementation of Quality Prevention of Mother to Child Transmission (PMTCT) Activities in the Republic of Uganda Apply for CDC RFA PS04 230 Funding Number: CDC RFA PS04 230 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Strengthening Public Health Capacity and Strategic Information Systems through Cooperation with the Joint United Nations Programme on HIV/AIDS (UNAIDS) under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10157 Funding Number: CDC RFA PS10 10157 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Providing Capacity Building Assistance to Governmental and Indigenous Organizations in order to Improve the Delivery of HIV/AIDS Services in the Democratic Republic of Congo Under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10101 Funding Number: CDC RFA PS10 10101 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Family Centered Substance Abuse Treatment Grants for Adolescents and their Families Apply for TI 10 002 Funding Number: TI 10 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
| Improving availability of safe blood transfusion services through a mentoring technical assistance (TA) relationship with The Nigerian National Blood Transfusion Service, to ensure a sustainable quality management system in the Federal Republic of Ni Apply for CDC RFA PS10 1039 Funding Number: CDC RFA PS10 1039 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Strengthening the Capacity of the Republican AIDS Center to implement HIV Programs in the Kyrgyz Republic under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10163 Funding Number: CDC RFA PS10 10163 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Strengthening the Capacity of the Republican AIDS Center to Implement HIV Programs in the Republic of Kazakhstan under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10164 Funding Number: CDC RFA PS10 10164 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 11 005", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.